High-Performance Humanized Control Antibodies to Advance Infectious Disease Diagnostics

0
74

The main categories of infectious diseases include: 1) viral infections (e.g. SARS-CoV-2, influenza, HIV, dengue fever and hepatitis B and C); 2) bacterial infections (e.g. tuberculosis, salmonellosis and Lyme disease); 3) parasitic infections (e.g. malaria and leishmaniasis); 4) fungal infections (e.g. candidiasis and histoplasmosis); 5) prion diseases (e.g. Creutzfeldt-Jakob disease, fatal familial insomnia, Kuru and protease-sensitive prion diseases).

Antibodies are indispensable in diagnosing and treating diseases caused by pathogens and their toxins. Over a century ago, antibodies were first incorporated into the medical arsenal for combating infectious diseases by using animal sera to treat tetanus and diphtheria. Today, most therapeutic antibodies are developed primarily to target cancer or autoimmune diseases. The COVID-19 pandemic has once again highlighted the importance of antibodies in treating infectious diseases.

Creative Diagnostics currently offers over 200 humanized control antibodies for infectious disease diagnostics, covering more than 50 clinically relevant pathogens, including viral, bacterial, parasitic, and fungal targets. These control antibodies are suitable for a wide range of applications, including the development and optimization of diagnostic assays, analytical and clinical validation studies, calibration and positive control materials, routine quality control in diagnostic laboratories, and diagnostic kit manufacturing and regulatory testing.

Compared to traditional serum-derived controls, humanized control antibodies offer several advantages, including enabling serum-free production. Creative Diagnostics' antibodies are produced using a recombinant expression system and contain no animal-derived serum components. This approach reduces the risk of contamination, minimizes background interference and enhances reagent purity.

Furthermore, recombinant antibody technology ensures precise control over antibody sequence and structure, thereby minimizing variation between batches. These antibodies exhibit long-term stability during storage and transport, ensuring consistent assay performance. Unlike human serum controls, recombinant antibodies can be produced consistently and on a large scale. This provides diagnostic kit manufacturers and clinical laboratories with a reliable supply chain.

In addition, Creative Diagnostics' humanized control antibodies are compatible with a wide range of immunoassay technologies, including ELISA, CLIA and chemiluminescence platforms, as well as rapid diagnostic tests such as lateral flow assays. This product portfolio covers a wide range of infectious disease targets commonly used in clinical diagnostics, including viral pathogens such as HIV, hepatitis viruses, influenza viruses and emerging respiratory viruses, as well as important bacterial, parasitic and fungal pathogens.

For more information about the Humanized Control Antibodies or to explore the full range of diagnostic reagents, please visit https://www.creative-diagnostics.com/humanized-control-antibodies-for-infectious-disease-diagnostics.htm.

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers' assay development and manufacturing needs.

Site içinde arama yapın
Sponsorluk
Kategoriler
Read More
Other
One Union Solutions: How Pallet Optimization in Logistics Improves Supply Chain Efficiency
In contemporary competitive worldwide marketplace, businesses are continuously attempting to find...
By OneUnion Solutions 2026-06-29 13:04:02 1 1K
Shopping
รีวิว relx บุหรี่อิเล็กทรอนิกส์ เปรียบเทียบ ราคาบุหรี่ไฟฟ้า และจุดเด่นของ เครื่อง RELX รุ่นล่าสุด
ในปัจจุบันกระแสของบุหรี่ไฟฟ้าเติบโตอย่างรวดเร็วในประเทศไทย โดยเฉพาะผลิตภัณฑ์จากแบรนด์ RELX...
By Chen Chen 2025-08-18 03:49:06 0 654
Networking
Solvent Recycling System Market Global Updates | Research Overview 2025 to 2034
  The Solvent Recycling System Market Is Set To Grow At An Estimated CAGR Of 4.6% From 2025...
By Tejaswini Aarote 2025-04-11 06:44:24 0 1K
Uncategorized
Advanced Cancer Research Initiatives Drive Growth Across the Ovarian Cancer Industry
The global ovarian cancer market is experiencing remarkable expansion as advancements...
By Violet Mac 2026-06-15 07:34:12 0 418
Uncategorized
Why Medium Density Polyethylene Market Will Witness Strong Growth by 2031
Across the spectrum of polyethylene grades, medium density polyethylene occupies a strategically...
By Peater Thomas 2026-05-26 11:05:28 0 677
Talkfever - Growing worldwide https://talkfever.com/